Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial

Vaccine

Volumn 24, Issue 18, 2006, Pages 3735-3745

  McKenzie, R ^a   Walker, R I ^b   Nabors, G S ^b   Verg, L L Van De ^b   Carpenter, C ^a   Gomes, G ^a   Forbes, E ^b   Tian, J H ^b   Yang, H H ^b   Pace, J L ^b   Jackson, W J ^b   Bourgeois, A L ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Emergent Biosolutions   (United States)

Author keywords

Inactivated; Oral; Shigella; Vaccine

Indexed keywords

DEOXYCHOLIC ACID; FORMALDEHYDE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INACTIVATED VACCINE; PLACEBO; SHIGELLA VACCINE;

ABDOMINAL PAIN; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIUM ADHERENCE; BACTERIUM CULTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; GASTROINTESTINAL SYMPTOM; GEOMETRY; GUINEA PIG; HUMAN; IMMUNOGENICITY; IMMUNOGLOBULIN BLOOD LEVEL; KERATOCONJUNCTIVITIS; MALE; NAUSEA; NONHUMAN; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SERUM; SHIGELLA SONNEI; SHIGELLOSIS; STATISTICAL SIGNIFICANCE; VOMITING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; DISEASE MODELS, ANIMAL; DYSENTERY, BACILLARY; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FIXATIVES; FORMALDEHYDE; GUINEA PIGS; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; KERATOCONJUNCTIVITIS; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; PLACEBOS; SHIGELLA SONNEI; SHIGELLA VACCINES; VACCINES, INACTIVATED;

EID: 33646474256     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2005.07.014     Document Type: Article

References (33)

1. Kotloff K.L., Winickoff J.P., Ivanoff B., Clemens J.D., Swerdlow D.L., Sansonetti P.J., et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull WHO 77 (1999) 651-667
2. Noriega F.R., Liao F.M., Maneval D.R., Ren S., Formal S.B., and Levine M.M. Strategy for cross-protection among Shigella flexneri serotypes. Infect Immun 67 2 (1999) 782-788
3. Mel D., Gangarosa E.J., Radovanovic M.L., Arsic B.L., and Litvinjenko S. Studies on vaccination against bacillary dysentery. Bull WHO 45 (1971) 457-464
4. Coster T.S., Hoge C.W., Van De Verg L.L., Hartman A.B., Oaks E.V., Venkatesan M.M., et al. Vaccination against shigellosis with attenuated Shigella flexneri 2a strain SC602. Infect Immun 67 7 (1999) 3437-3443
5. Kotloff K.L., Taylor D.N., Sztein M.B., Wasserman S.S., Losonsky G.A., Nataro J.P., et al. Phase I evaluation of delta virG Shigella sonnei live, attenuated, oral vaccine strain WRSS1 in healthy adults. Infect Immun 70 4 (2002) 2016-2021
6. Katz D.E., Coster T.S., Wolf M.K., Trespalacios F.C., Cohen D., Robins G., et al. Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. Infect Immun 72 2 (2004) 923-930
7. Levine M.M., Gangarosa E.J., Barrow W.B., and Weiss C.F. Shigellosis in custodial institutions. V. Effect of intervention with streptomycin-dependent Shigella sonnei vaccine in an institution with endemic disease. Am J Epidemiol 104 1 (1976) 88-92
8. Herrington D.A., Van De Verg L.L., Formal S.B., Hale T.L., Tall B.D., Cryz S.J., et al. Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. Vaccine 8 4 (1990) 353-357
9. DuPont H.L., Hornick R.B., Snyder M.J., Libonati J.P., Formal S.B., and Gangarosa E.J. Immunity in shigellosis. I. Response of man to attenuated strains of Shigella. J Infect Dis 125 1 (1972) 5-11
10. Cohen D., Ashkenazi S., Green M.S., Gdalevich M., Robin G., Slepon R., et al. Double-blind vaccine-controlled radomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. Lancet 349 (1997) 155
11. Evans D.G., Evans Jr. D.J., Opekun A.R., and Graham D.Y. Non-replicating oral whole cell vaccine protective against enterotoxigenic Escherichia coli (ETEC) diarrhea: stimulation of anti-CFA (CFA/I) and anti-enterotoxin (anti-LT) intestinal IgA and protection against challenge with ETEC belonging to heterologous serotypes. FEMS Microbiol Immunol 1 3 (1988) 117-125
12. Clemens J.D., Sack D.A., Harris J.R., Van Loon F., Chakraborty J., Ahmed F., et al. Field trial of oral cholera vaccines in Bangladesh: results from 3-year follow-up. Lancet 335 8684 (1990) 270-273
13. Sanchez J.L., Vasquez B., Begue R.E., Meza R., Castellares G., Cabezas C., et al. Protective efficacy of oral whole-cell/recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet 344 8932 (1994) 1273-1276
14. Trach D.D., Clemens J.D., Ke N.T., Thuy H.T., Son N.D., Canh D.G., et al. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. Lancet 349 9047 (1997) 231-235
15. Clemens J.D., Sack D.A., Harris J.R., Chakraborty J., Neogy P.K., Stanton B., et al. Cross-protection by B subunit-whole cell cholera vaccine against diarrhea associated with heat-labile toxin-producing enterotoxigenic Escherichia coli: results of a large-scale field trial. J Infect Dis 158 2 (1988) 372-377
16. Peltola H., Siitonen A., Kyronseppa H., Simula I., Mattila I., Oksanen P., et al. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet 338 8778 (1991) 1285-1289
17. Cohen D., Green M.S., Block C., Rouach T., and Ofek I. Serum antibodies to lipopolysaccharide and natural immunity to shigellosis in an Israeli military population. J Infect Dis 157 5 (1988) 1068-1071
18. Cohen D., Green M.S., Block C., Slepon R., and Ofek I. Prospective study of the association between serum antibodies to lipopolysaccharide O antigen and the attack rate of shigellosis. J Clin Microbiol 29 2 (1991) 386-389
19. Cohen D., Green M.S., Block C., Slepon R., and Lerman Y. Natural immunity to shigellosis in two groups with different previous risks of exposure to Shigella is only partly expressed by serum antibodies to lipopolysaccharide. J Infect Dis 165 4 (1992) 785-787
20. Oberhelman R.A., Kopecko D.J., Salazar-Lindo E., Gotuzzo E., Buysse J.M., Venkatesan M.M., et al. Prospective study of systemic and mucosal immune responses in dysenteric patients to specific Shigella invasion plasmid antigens and lipopolysaccharides. Infect Immun 59 7 (1991) 2341-2350
21. Van de Verg L.L., Herrington D.A., Boslego J., Lindberg A.A., and Levine M.M. Age-specific prevalence of serum antibodies to the invasion plasmid and lipopolysaccharide antigens of Shigella species in Chilean and North American populations. J Infect Dis 166 1 (1992) 158-161
22. Pope L.M., Reed K.E., and Payne S.M. Increased protein secretion and adherence to HeLa cells by Shigella spp. following growth in the presence of bile salts. Infect Immun 63 9 (1995) 3642-3648
23. Buysse J.M., Stover C.K., Oaks E.V., Venkatesan M., and Kopecko D.J. Molecular cloning of invasion plasmid antigen (ipa) genes from Shigella flexneri: analysis of ipa gene products and genetic mapping. J Bacteriol 169 6 (1987) 2561-2569
24. Westphal O., and Jann K. Bacterial lipopolysaccharides. Extractions with phenol-water and further applications of the procedure. Methods Carbohydr Chem 5 (1965) 83-91
25. Dickinson B.L., and Clements J.D. Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun 63 5 (1995) 1617-1623
26. Sereny B. Experimental keratoconjunctivitis shigellosa. Acta Microbiol Acad Sci Hung 4 (1957) 367-376
27. Munoz C., Baqar S., Van De Verg L.L., Thupari J., Goldblum S., Olson J.G., et al. Characteristics of Shigella sonnei infection of volunteers: signs, symptoms, immune responses, changes in selected cytokines and acute-phase substances. Am J Trop Med Hyg 53 1 (1995) 47-54
28. Chakrabarti M.K., Bhattacharya J., Bhattacharya M.K., Nair G.B., Bhattacharya S.K., and Mahalanabis D. Killed oral Shigella vaccine made from Shigella flexneri 2a protects against challenge in the rabbit model of shigellosis. Acta Paediatr 88 2 (1999) 161-165
29. Hartman A.B., Van de Verg L.L., and Venkatesan M.M. Native and mutant forms of cholera toxin and heat-labile enterotoxin effectively enhance protective efficacy of live attenuated and heat-killed Shigella vaccines. Infect Immun 67 11 (1999) 5841-5847
30. Mukhopadhaya A., Mahalanabis D., Khanam J., and Chakrabarti M.K. Protective efficacy of oral immunization with heat-killed Shigella flexneri 2a in animal model: study of cross protection, immune response and antigenic recognition. Vaccine 21 2122 (2003) 3043-3050
31. Formal S.B., LaBrec E.H., Palmer A., and Falkow S. Protection of Monkeys Against Experimental Shigellosis with Attenuated Vaccines. J Bacteriol 90 (1965) 63-68
32. Kirkpatrick B.D., Fries L.F., Shimko J., Bourgeois A.L., Maple P., Gomes G., et al. Validation of a volunteer model of shigellosis due to shigella sonnei. [Abstract] (2000), ASTMH, Houston, Texas
33. Passwell J.H., Ashkenazi S., Harlev E., Miron D., Ramon R., Farzam N., et al. Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in 1-4-year-old children. Pediatr Infect Dis J 22 8 (2003) 701-706